Oppenheimer & Co’s Prime Medicine PRME Stock Holding History

Oppenheimer & Co’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$244K	Buy	79,914 +50,264	+170%	+$167K	﹤0.01%	1531
2026 Q2	$109K	Sell	29,650 -4,006	-12%	-$13.3K	﹤0.01%	1717
2026 Q1	$117K	Buy	33,656 +21,223	+171%	+$80.8K	﹤0.01%	1630
2025 Q4	$43.1K	Buy	+12,433	New	+$55.3K	﹤0.01%	1516
2025 Q1	–	Sell	-12,106	Closed	-$35.4K	–	1635
2024 Q4	$35.4K	Sell	12,106 -5,765	-32%	-$20.2K	﹤0.01%	1532
2024 Q3	$69.2K	Sell	17,871 -3,160	-15%	-$14.6K	﹤0.01%	1471
2024 Q2	$108K	Buy	21,031 +855	+4%	+$5.18K	﹤0.01%	1382
2024 Q1	$141K	Sell	20,176 -422	-2%	-$3.2K	﹤0.01%	1374
2023 Q4	$182K	Sell	20,598 -939	-4%	-$7.23K	﹤0.01%	1296
2023 Q3	$205K	Buy	21,537 +6,152	+40%	+$79.9K	﹤0.01%	1259
2023 Q2	$225K	Buy	15,385 +267	+2%	+$3.73K	﹤0.01%	1254
2023 Q1	$186K	Buy	15,118 +1,106	+8%	+$18K	﹤0.01%	1269
2022 Q4	$260K	Buy	+14,012	New	+$253K	0.01%	1134

Other funds holding PRME

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Alessandra Capital Management Torrance, California $142M AUM 42.73% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 25.53% 1-Year Est. Return

MAM

Milestone Asset Management Pittsburgh, Pennsylvania $631M AUM 19.95% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Oppenheimer & Co's PRME Position: Q3 2026 in Review

Oppenheimer & Co increased its Prime Medicine (PRME) stake by 170% in Q3 2026, buying an estimated $167K and bringing the position to 79,914 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #1531.

Oppenheimer & Co first reported a position in PRME in Q4 2022 and has held it in 13 quarters since. The position peaked at $260K in Q4 2022. 46 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

Oppenheimer & Co held 79,914 shares of Prime Medicine worth $244K as of Q3 2026.
Oppenheimer & Co bought 50,264 Prime Medicine shares in Q3 2026, an estimated $167K.
Prime Medicine made up ﹤0.01% of Oppenheimer & Co's portfolio in Q3 2026, its #1531 holding.
Oppenheimer & Co first reported a position in Prime Medicine in Q4 2022 and has held it in 13 quarters since.
Oppenheimer & Co's Prime Medicine position peaked at $260K in Q4 2022.
46 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on Oppenheimer & Co's 13F filing for Q3 2026, filed 26 Oct 2026.